IIT Professor Menhart Available To Speak About Eteplirsen
Drug Shows Tremendous Promise for Treatment of Duchenne Muscular Dystrophy
Some sources believe the FDA may approve the drug within 30 days
April 11, 2014—CHICAGO - Professor Nicholas Menhart of the Illinois Institute of Technology (IIT) is available to speak about eteplirsen, the new drug that is showing tremendous promise for the treatment of Duchenne muscular dystrophy (DMD).
Eteplirsen works by skipping defective exons in dystrophin. Menhart is an expert in dystrophin and exon-skipping. He can explain the mechanics of dystrophin—how it works normally, and how faulty dystrophin leads to muscular dystrophy.
- He can detail why and how eteplirsen appears to work, and provide illustrations or other material as needed to support understanding.
- He can also explain why the drug seems to work better than others, such as Prosensa/Glaxo SmithKline's drisapersen, which recently failed in a Phase III trial.
- Menhart's research is funded by the Muscular Dystrophy Association (MDA), and he has received funding from the National Institutes of Health and other sources.
Contact him at menhart@iit.edu or contact Patty Cronin, director of marketing for the IIT College of Science, at 312-567-3132 or cronin@iit.edu.
